In a regulatory filing, Gossamer Bio disclosed that its CEO Faheem Hasnain bought 372K shares of common stock on June 21st in a total transaction size of $250K.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Biotech Alert: Searches spiking for these stocks today
- Aerovate Therapeutics downgraded to Neutral from Buy at Guggenheim
- Gossamer Bio rises following competitorâs failure in PAH trial
- Goldman says PAH opportunity now incrementally more attractive for Gossamer Bio
- Gossamer Bio reports Q1 EPS (19c), consensus (19c)